Active Ingredient(s): Telbivudine
FDA Approved: * October 25, 2006
Pharm Company: * IDENIX PHARMA
Category: Hepatitis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tyzeka Overview

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3] However, HBV signature resistance mutation M204I (a change from methionine to isoleucine at positi...

Read more Tyzeka Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Telbivudine

Recent Tyzeka Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Solution: 100mg/5ml, 600mg
  • Tablet: 600mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tyzeka: (2 results)

Sorted by National Drug Code
  • 0078-0538 Tyzeka 600 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0539 Tyzeka 20 mg/ml Oral Solution by Novartis Pharmaceuticals Corporation

Other drugs which contain Telbivudine or a similar ingredient: (1 result)